Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Low Leverage ⢠Cash Flow TCMD has strong liquidity, low leverage, and solid profitability, but its elevated valuation and softer quarterly cash flow warrant disciplined entry timing.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Failed rebound ⢠Weak momentum Support Level: $21.73 Resistance Level: $22.50â$22.60 TCMD remains bearish over the last month, with a failed rebound and weak momentum; watch $21.73 support, while a sustained break above $22.60 would improve the outlook.
AI Summary
TCMD is now an execution-and-reacceleration investment: its strong balance sheet limits downside from financial distress, but investors should wait for revenue delivery within $360â$366M guidance, stable margins, and improved free-cash-flow conversion before underwriting a rerating or assigning value to the unproven battery-powered device.
Description
Tactile Systems Technology, Inc. is a U.S.-based medical device company that produces and markets noninvasive therapies for chronic conditions. Its product portfolio includes pneumatic compression systems for lymphedema and other venous disorders and a portable chest wall oscillation device for managing retained pulmonary secretions. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | TCMD | Tactile Systems Technology, Inc. | Q4 beat with 21% revenue growth, margin expansion, deleveraging (term loan repaid), and a buyback plus positive clinical data for Flexitouch have produced a sharp breakout (~10% over 21 days, 15% above the 21-day SMA); near-term upside is supported by strong fundamentals and follow-through on payer/volume metrics. | Closed | +5.9% |